Answers are grounded in this paper and cite their sources.
The Case-Patient A 56-year-old man from New England with a history of mantle cell lymphoma in remission, receiving maintenance rituximab since 2014, had fatigue, arthralgias, and weight loss in summer 2017.He was empirically treated for Lyme disease without improvement, had progressive insomnia and inattention, and was eventually admitted for workup of rapidly progressive dementia in April 2018.On examination, he had impaired arousal and attention (Montreal Cognitive Assessment score 6 of 30).
No takes yet. Share an insight, caveat, or question.
Solomon et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: